CeriBell, Inc.（CBLL）资讯与事件CBLLCeriBell, Inc.

Company Updates Outlook, Expects Revenue Growth of 28%-31%

Consensus $114M. The updated outlook represents growth of approximately 28% to 31% over the company's prior year revenue. This reflects continued momentum in its core business, driven by both new account additions and increased utilization within its established account base. "Combined with the early progress of our delirium pilot and multiple new FDA 510(k) clearances, we are highly confident in the strength of our business and our mission to establish EEG as a new vital sign," said CEO Jane Chao.

Company Reports Q2 Revenue of $28.1M, Beating Expectations

Reports Q2 revenue $28.1M, consensus $27.28M. Total revenue increased 33% year-over-year, driven primarily by continued growth in new account additions and increased utilization within existing accounts. "Our second quarter results reflect adoption accelerating across both new and existing accounts," said co-founder and CEO Jane Chao.

Company Reports Q1 Revenue of $26.5M, Exceeding Expectations

Reports Q1 revenue $26.5M, consensus $26.09M. "Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure monitoring platform," said co-founder and CEO Jane Chao, Ph.D. "The launch of our neonate and pediatric offerings represents a major milestone in our commitment to provide critical brain monitoring for patients of all ages. As we work to redefine the standard of care in seizure management, we will continue to invest in innovation and expansion of our clinical indications to advance our mission to make EEG a new vital sign."